Venetoclax
規格
1257044-40-8CAS番号
820-130-9EC番号
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideIUPAC名
C45H50ClN7O7S化学式
868.4 g/mol分子量
Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199; ABT199; venclyxto; ABT 199; RG7601; GDC 0199; RG-7601; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N54AIC43PW; Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-; CHEBI:133021; DTXSID30154863; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; venetoclaxum; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzenesulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(oxan-4-ylmethylamino)phenyl)sulfonyl-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((4'-chloro-5,5-dimethyl(3,4,5,6-tetrahydro(1,1'-biphenyl))-2-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzene-1-sulfonyl)-2-((1H-pyrrolo(2,3-b)pyridin-5-yl)oxy)benzamide; RefChem:58112; DTXCID0077354; L01XX52; ABT-0199; Venetoclax (ABT-199); Venetoclax (ABT199); UNII-N54AIC43PW; C45H50ClN7O7S; MFCD23160052; Venetoclax; Abt-199; ABT 199 (Venetoclax); 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide; ABT-199 (GDC-0199); 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; BDBM189459; ABT 199 (>99%)(Venetoclax); 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venetoclax [USAN:INN]; Venclexta (TN); ABBVIE; Venetoclax (Standard); VENETOCLAX [MI]; Venetoclax(ABT-199); VENETOCLAX [INN]; VENETOCLAX [JAN]; VENETOCLAX [USAN]; Venetoclax(ABT-199)?; VENETOCLAX [WHO-DD]; MLS006010298; SCHEMBL523816; Venetoclax (JAN/USAN/INN); GTPL8318; orb1226663; orb1306442; orb3141366; CHEMBL3137309; SCHEMBL19236295; SCHEMBL29353714; SCHEMBL29360081; SCHEMBL29390802; SCHEMBL29801595; VENETOCLAX [ORANGE BOOK]; BDBM60828; EX-A168; GLXC-06797; HMS3653J06; HMS3745E07; HMS5086M05; BDBM50162774; EBC-17182; HY-15531R; NSC766270; AKOS025289539; CCG-270543; CS-1155; DB11581; FV63222; KS-1470; NSC-766270; SB16499; NCGC00345789-01; NCGC00345789-03; NCGC00345789-04; NCGC00345789-05; NCGC00345789-10; NCGC00345789-11; NCGC00345789-12; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; AC-28754; BP-43649; DA-35360; HY-15531; SMR004701366; SY048011; CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY; NS00073446; SW219672-1; T2119; D10679; US9174982, 5; EN300-7399830; US9174982, 369; BRD-K62391742-001-03-0; BRD-K62391742-001-08-9; BRD-K62391742-001-09-7; Q23671272; Z2037279542; )methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 2-[[Pyrrolo[2,3-b]pyridin-5-yl]oxy]-4-[4-[[4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-2-biphenylyl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(4-tetrahydropyranyl)methyl]amino]phenyl]sulfonyl]benzamide; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; ABT-199; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; VENETOCLAXVENCLEXTAABT-199A-12314-[4-[[2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL]PIPERAZIN-1-YL]-N-[[3-NITRO-4-[[(TETRAHYDRO-2H-PYRAN-4-YL)METHYL]AMINO]PHENYL]SULFONYL]-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE別名
Venetoclaxを含む製品
벤클렉스타정50밀리그램(베네토클락스)벤클렉스타정10밀리그램(베네토클락스)벤클렉스타정100밀리그램(베네토클락스)VENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 mg, comprimé pelliculéVENCLYXTO 100 mg, comprimé pelliculéVENCLYXTO 10 mg, comprimé pelliculéVenetoclax - Changzhou Pharmaceutical Factory
1/4ページ
Venetoclaxを販売する企業
MP
Macleods Pharmaceuticals LimitedIndiaAD
Abbvie Deutschland GmbH & Co. KGGermanyDR
Dr. Reddy's LaboratoriesIndiaML
MSN LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.China1/3ページ